RBC Capital Maintains Outperform on Korro Bio, Lowers Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi maintains an Outperform rating on Korro Bio (NASDAQ:KRRO) but lowers the price target from $105 to $95.
August 14, 2024 | 3:35 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital analyst Luca Issi maintains an Outperform rating on Korro Bio but lowers the price target from $105 to $95.
The Outperform rating suggests continued confidence in Korro Bio's performance, but the lowered price target indicates some tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100